Opinion

Video

Overview of RSV Patient Populations

Author(s):

Ryan Haumschild, PharmD, MS, MBAWanda Filer, MD, MBA

A panel of experts on respiratory syncytial virus (RSV) introduce themselves and give an overview of patients who are most affected by RSV.

Video content above is prompted by the following questions:

  • Which patient groups are most affected by RSV? Who would be a high-risk adult patient for RSV?
    • Do comorbidities, such as cardiovascular or respiratory diseases, predispose patients to more severe infections?
Related Videos
A panel of 5 experts on Alzheimer disease
A panel of 5 experts on Alzheimer disease
Marty J. Feltner, PharmD, an expert on RSV
A panel of 4 experts on PDTs
A panel of 5 experts on Alzheimer disease
A panel of 5 experts on Alzheimer disease
Related Content
Vaccine booster concept faded background | MargJohnsonVA - stock.adobe.com
June 26th 2024

Why Are Some Parents Still Hesitant to Vaccinate Their Child Against RSV?

Pearl Steinzor
Increasing knowledge of the vaccine-preventable disease will ultimately improve vaccine uptake among target groups, researchers suggest.
RSV vaccine vial with syringe - Respiratory syncytial virus shot | MargJohnsonVA - stock.adobe.com
June 18th 2024

Simultaneous RSV, Influenza Vaccination Found Safe in Patients With High-Risk Heart Failure

Pearl Steinzor
Vaccination against seasonal influenza and respiratory syncytial virus (RSV) in patients with high-risk heart failure was found safe with low incidence of mild adverse events (AEs).
RSV vaccine | Peter Hansen - stock.adobe.com
June 11th 2024

FDA Approves Expanded Age Indication for RSV Vaccine Arexvy

Pearl Steinzor
The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk.
Sick child in hospital-Rawpixel.com-stock.adobe.com.jpeg
June 7th 2024

How COVID-19 Has Impacted RSV Epidemiology Among Children in a Hospital Setting

Pearl Steinzor
Respiratory syncytial virus (RSV) hospitalization–related features may help inform prevention approaches among children with the infection, according to one study.
FDA approval | Image Credit: MargJohnsonVA - stock.adobe.com
May 31st 2024

Moderna Receives FDA Nod for Single-Dose RSV mRNA Vaccine

Cameron Santoro
The FDA approved mRNA-1345, a Moderna vaccine for the treatment of respiratory syncytial virus (RSV). This single-dose vaccine offers protection against lower respiratory tract disease in adults over 60 years, with data suggesting long-term effectiveness.
Boy at doctor's office
August 31st 2023

Airway Narrowing Common in Patients With RSV Acute Bronchiolitis

Julia Bonavitacola
Lung sound analysis was able to confirm airway narrowing in patients with respiratory syncytial virus (RSV) acute bronchiolitis.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo